Literature DB >> 2186663

Suxamethonium and hyperkalaemia.

S M Yentis1.   

Abstract

Severe life-threatening hyperkalaemia may occur following administration of suxamethonium during certain periods after burns, neurological injuries, and in certain other conditions. Although this response is well-known, there is disagreement about when it may occur. This review describes the normal hyperkalaemic response to suxamethonium, the factors affecting it, the conditions in which it may be exaggerated, and the periods of high risk.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2186663     DOI: 10.1177/0310057X9001800114

Source DB:  PubMed          Journal:  Anaesth Intensive Care        ISSN: 0310-057X            Impact factor:   1.669


  6 in total

1.  [Primary treatment of burn patients].

Authors:  G A Giessler; R Deb; G Germann; M Sauerbier
Journal:  Chirurg       Date:  2004-06       Impact factor: 0.955

Review 2.  The pulmonary physician in critical care. 11: critical care management of respiratory failure resulting from COPD.

Authors:  A C Davidson
Journal:  Thorax       Date:  2002-12       Impact factor: 9.139

3.  Ventricular fibrillation and rhabdomyolysis after administration of succinylcholine.

Authors:  R L Braam; J K J Deegens; H J G Jessen; A J M Oude Ophuis; B T J Meursing
Journal:  Neth Heart J       Date:  2003-12       Impact factor: 2.380

4.  Anesthetic management during Cesarean section in a woman with residual Arnold-Chiari malformation Type I, cervical kyphosis, and syringomyelia.

Authors:  Ramsis F Ghaly; Kenneth D Candido; Ruben Sauer; Nebojsa Nick Knezevic
Journal:  Surg Neurol Int       Date:  2012-02-15

Review 5.  Pharmacology, selection and complications associated with neuromuscular blocking drugs in ICU patients.

Authors:  R C Prielipp
Journal:  Yale J Biol Med       Date:  1998 Nov-Dec

6.  Is succinylcholine appropriate or obsolete in the intensive care unit?

Authors:  L H Booij
Journal:  Crit Care       Date:  2001-08-31       Impact factor: 9.097

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.